CompletedPhase 1NCT01879683

A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions

Studying Interstitial cystitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Allergan
Principal Investigator
Kenneth Peters, MD
Corewell Health East
Intervention
LiRIS® 400 mg(drug)
Enrollment
10 target
Eligibility
18 years · FEMALE
Timeline
20132014

Study locations (2)

Collaborators

TARIS Biomedical, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01879683 on ClinicalTrials.gov

Other trials for Interstitial cystitis

Additional recruiting or active studies for the same condition.

See all trials for Interstitial cystitis

← Back to all trials